Regeneron quarterly profit drops as COVID antibody sales hit (US.REGN)
The drugmaker's net profit in the first quarter ended March 31 fell to $974 million, or $8.61 per share, from $1.12 billion, or $10.09 per share, a year earlier.
Its blockbuster eye treatment Eylea and eczema therapy Dupixent, however, performed well, recording sales growth of 11% and 43%, respectively.
Gradual easing of lockdowns amid increasing vaccinations has boded well for physician-administered eye treatment Eylea over the last few quarters.
Sales of Dupixent also helped Regeneron's overall sales grow 17% to $2.97 billion.
1 regeneron quarterly profit drops 06852.html?.tsrc=fin srch1050